8-KItem 2.05 · Exit/Disposal Costs
Boston Scientific approves restructuring plan with up to $800 million in charges
Filed with the SEC on · Summarized by InvestorsBot
Boston Scientific’s board approved a global restructuring plan on July 21, 2026, involving supply-chain changes, production-line transfers, organizational changes and some headcount reductions through 2029. The plan is expected to generate $700 million to $800 million in pre-tax charges, including $600 million to $700 million in future cash costs, while reducing annual pre-tax expenses by about $500 million as benefits are realized.